These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 33278600)

  • 1. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT
    Cottereau AS; Meignan M; Nioche C; Capobianco N; Clerc J; Chartier L; Vercellino L; Casasnovas O; Thieblemont C; Buvat I
    Ann Oncol; 2021 Mar; 32(3):404-411. PubMed ID: 33278600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of metabolic tumor volume and lesion dissemination from baseline PET/CT in patients with diffuse large B-cell lymphoma: Further risk stratification of the group with low-risk and high-risk NCCN-IPI.
    Xu H; Ma J; Yang G; Xiao S; Li W; Sun Y; Sun Y; Wang Z; Zhao H
    Eur J Radiol; 2023 Jun; 163():110798. PubMed ID: 37030099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
    Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of metabolic tumour volume on baseline
    Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY; Guo Z; Sun J; Yang WP; Li TR
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
    [No Abstract]   [Full Text] [Related]  

  • 6. Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial.
    Girum KB; Cottereau AS; Vercellino L; Rebaud L; Clerc J; Casasnovas O; Morschhauser F; Thieblemont C; Buvat I
    J Nucl Med; 2024 Feb; 65(2):313-319. PubMed ID: 38071535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of Dmax and %ΔSUVmax of
    Dang J; Peng X; Wu P; Yao Y; Tan X; Ye Z; Jiang X; Jiang X; Liu Y; Chen S; Cheng Z
    BMC Med Imaging; 2023 Oct; 23(1):173. PubMed ID: 37907837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissemination feature based on PET/CT is a risk factor for diffuse large B cell lymphoma patients outcome.
    Wang F; Cui S; Lu L; Shao X; Yan F; Liu Y; He B; Wang J; Cao Y; Yue Y; Wang Y; Gu W
    BMC Cancer; 2023 Nov; 23(1):1165. PubMed ID: 38030989
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Girum KB; Rebaud L; Cottereau AS; Meignan M; Clerc J; Vercellino L; Casasnovas O; Morschhauser F; Thieblemont C; Buvat I
    J Nucl Med; 2022 Dec; 63(12):1925-1932. PubMed ID: 35710733
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Cottereau AS; Nioche C; Dirand AS; Clerc J; Morschhauser F; Casasnovas O; Meignan M; Buvat I
    J Nucl Med; 2020 Jan; 61(1):40-45. PubMed ID: 31201248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A nomogram for predicting the rapid progression of diffuse large B-cell lymphoma established by combining baseline PET/CT total metabolic tumor volume, lesion diffusion, and TP53 mutations.
    Liu C; Shi P; Li Z; Li B; Li Z
    Cancer Med; 2023 Aug; 12(16):16734-16743. PubMed ID: 37366281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of the baseline 18F-FDG PET/CT metabolic tumour volume (MTV) and further stratification in low-intermediate (L-I) and high-intermediate (H-I) risk NCCNIPI subgroup by MTV in DLBCL MTV predict prognosis in DLBCL.
    Zhao P; Yu T; Pan Z
    Ann Nucl Med; 2021 Jan; 35(1):24-30. PubMed ID: 33001389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Approaches in Characterization of Lesions Dissemination in DLBCL Patients on Baseline PET/CT.
    Cottereau AS; Meignan M; Nioche C; Clerc J; Chartier L; Vercellino L; Casasnovas O; Thieblemont C; Buvat I
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of baseline
    Xia L; Li X; Zhu J; Gao Z; Zhang J; Yang G; Wang Z
    Radiat Oncol; 2023 Feb; 18(1):41. PubMed ID: 36829219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [
    Xu HQ; Song LJ; Ding CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1690-1700. PubMed ID: 38071047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.
    Song MK; Yang DH; Lee GW; Lim SN; Shin S; Pak KJ; Kwon SY; Shim HK; Choi BH; Kim IS; Shin DH; Kim SG; Oh SY
    Leuk Res; 2016 Mar; 42():1-6. PubMed ID: 26851438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic Value of
    Su JM; Zheng QZ; Huang WR; Deng J; Wu J; Lu HQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1181-1186. PubMed ID: 34362500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
    Wu LL; Liang JH; Wang L; Xu W; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.